Global Psychedelic Medicine Market

Psychedelic Medicine Comprehensive Study by Application (Mental Health Disorders, Pain Management, End-of-Life Care, Existential Therapy), Drug Type (Psilocybin, Ketamine, MDMA, LSD, Ibogaine, Ayahuasca), End-User (Hospitals & Clinics, Clinical Research Organizations, Research Institutes), Delivery Method (Oral, Sublingual, Intravenous, Inhalation) Players and Region - Global Market Outlook to 2032

Psychedelic Medicine Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Psychedelic Medicine
Psychedelic medicine usually refers to relations formed between the use of psychedelic substances such as psilocybin, MDMA, and ayahuasca in an experimental session to treat a variety of mental disorders. This approach has gained popularity for its capability at treating a number of medical conditions, such as depression, anxiety, PTSD, addiction, and chronic pain. Psychedelic medicines seem to differ from other medication alternatives, as these shifts alter brain chemistry often leading to swift changes at the emotional or cognitive levels that lead to long-lasting therapeutic effects. A lot has transpired in psychedelic medicine in recent years, and the results from these clinical trials have been promising. Psilocybin has been linked to finding reductions in symptoms of depression and anxiety among terminally ill patients; MDMA has been shown to be quite effective among patients with PTSD. Such substances summon deep probing into human psyche and properties of compassion, in a unique way. Despite much possibility and bright future, psychedelic medicine is still in experimentation. A number of commonly used psychedelics are not yet approved for usage on the public. Besides, due to legal and regulatory restrictions, each enlargement of psychedelics on the convention attention may require further efforts to garner broad acceptance. If research continues on fair course, it is believed that the realm of psychedelic therapy could provide an alternative to conventional psychiatric drugs in what may offer hope to entire sub-populations of treatment-resistant patients.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca (Cambridge, United Kingdom), Cybin Corp. (Toronto, Canada), Jazz Pharmaceuticals Inc. (Dublin, Ireland), Pfizer Inc. (New York, United States), COMPASS Pathways (London, United Kingdom), Entheon Biomedical Corp (Vancouver, Canada), PharmaTher Holdings Ltd. (Toronto, Canada), F. Hoffmann-La Roche Ltd (Basel, Switzerland), Verrian (Wilmington, United States), Mind Medicine (New York, United States), Hikma Pharmaceuticals PLC (London, United Kingdom), Celon Pharmaceuticals (Warsaw, Poland), GH Research (Dublin, Ireland), NeonMind Biosciences (Vancouver, Canada) and Usona Institute (Madison, United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Psychedelic Medicine market by , Application (Mental Health Disorders, Pain Management, End-of-Life Care and Existential Therapy) and Region.



On the basis of geography, the market of Psychedelic Medicine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Psilocybin will boost the Psychedelic Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Hospitals & Clinics will boost the Psychedelic Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Delivery Method , the sub-segment i.e. Oral will boost the Psychedelic Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.



About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Mental Health Disorders
  • Pain Management
  • End-of-Life Care
  • Existential Therapy
By Drug Type
  • Psilocybin
  • Ketamine
  • MDMA
  • LSD
  • Ibogaine
  • Ayahuasca

By End-User
  • Hospitals & Clinics
  • Clinical Research Organizations
  • Research Institutes

By Delivery Method
  • Oral
  • Sublingual
  • Intravenous
  • Inhalation

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Factor Analysis
    • 3.1. Porters Five Forces
    • 3.2. Supply/Value Chain
    • 3.3. PESTEL analysis
    • 3.4. Market Entropy
    • 3.5. Patent/Trademark Analysis
  • 4. Global Psychedelic Medicine, by Application, Drug Type, End-User, Delivery Method and Region (value) (2019-2024)
    • 4.1. Introduction
    • 4.2. Global Psychedelic Medicine (Value)
      • 4.2.1. Global Psychedelic Medicine by: Application (Value)
        • 4.2.1.1. Mental Health Disorders
        • 4.2.1.2. Pain Management
        • 4.2.1.3. End-of-Life Care
        • 4.2.1.4. Existential Therapy
      • 4.2.2. Global Psychedelic Medicine by: Drug Type (Value)
        • 4.2.2.1. Psilocybin
        • 4.2.2.2. Ketamine
        • 4.2.2.3. MDMA
        • 4.2.2.4. LSD
        • 4.2.2.5. Ibogaine
        • 4.2.2.6. Ayahuasca
      • 4.2.3. Global Psychedelic Medicine by: End-User (Value)
        • 4.2.3.1. Hospitals & Clinics
        • 4.2.3.2. Clinical Research Organizations
        • 4.2.3.3. Research Institutes
      • 4.2.4. Global Psychedelic Medicine Region
        • 4.2.4.1. South America
          • 4.2.4.1.1. Brazil
          • 4.2.4.1.2. Argentina
          • 4.2.4.1.3. Rest of South America
        • 4.2.4.2. Asia Pacific
          • 4.2.4.2.1. China
          • 4.2.4.2.2. Japan
          • 4.2.4.2.3. India
          • 4.2.4.2.4. South Korea
          • 4.2.4.2.5. Taiwan
          • 4.2.4.2.6. Australia
          • 4.2.4.2.7. Rest of Asia-Pacific
        • 4.2.4.3. Europe
          • 4.2.4.3.1. Germany
          • 4.2.4.3.2. France
          • 4.2.4.3.3. Italy
          • 4.2.4.3.4. United Kingdom
          • 4.2.4.3.5. Netherlands
          • 4.2.4.3.6. Rest of Europe
        • 4.2.4.4. MEA
          • 4.2.4.4.1. Middle East
          • 4.2.4.4.2. Africa
        • 4.2.4.5. North America
          • 4.2.4.5.1. United States
          • 4.2.4.5.2. Canada
          • 4.2.4.5.3. Mexico
  • 5. Psychedelic Medicine: Manufacturers/Players Analysis
    • 5.1. Competitive Landscape
      • 5.1.1. Market Share Analysis
        • 5.1.1.1. Top 3
        • 5.1.1.2. Top 5
    • 5.2. Peer Group Analysis (2024)
    • 5.3. BCG Matrix
    • 5.4. Company Profile
      • 5.4.1. AstraZeneca (Cambridge, United Kingdom)
        • 5.4.1.1. Business Overview
        • 5.4.1.2. Products/Services Offerings
        • 5.4.1.3. Financial Analysis
        • 5.4.1.4. SWOT Analysis
      • 5.4.2. Cybin Corp. (Toronto, Canada)
        • 5.4.2.1. Business Overview
        • 5.4.2.2. Products/Services Offerings
        • 5.4.2.3. Financial Analysis
        • 5.4.2.4. SWOT Analysis
      • 5.4.3. Jazz Pharmaceuticals Inc. (Dublin, Ireland)
        • 5.4.3.1. Business Overview
        • 5.4.3.2. Products/Services Offerings
        • 5.4.3.3. Financial Analysis
        • 5.4.3.4. SWOT Analysis
      • 5.4.4. Pfizer Inc. (New York, United States)
        • 5.4.4.1. Business Overview
        • 5.4.4.2. Products/Services Offerings
        • 5.4.4.3. Financial Analysis
        • 5.4.4.4. SWOT Analysis
      • 5.4.5. COMPASS Pathways (London, United Kingdom)
        • 5.4.5.1. Business Overview
        • 5.4.5.2. Products/Services Offerings
        • 5.4.5.3. Financial Analysis
        • 5.4.5.4. SWOT Analysis
      • 5.4.6. Entheon Biomedical Corp (Vancouver, Canada)
        • 5.4.6.1. Business Overview
        • 5.4.6.2. Products/Services Offerings
        • 5.4.6.3. Financial Analysis
        • 5.4.6.4. SWOT Analysis
      • 5.4.7. PharmaTher Holdings Ltd. (Toronto, Canada)
        • 5.4.7.1. Business Overview
        • 5.4.7.2. Products/Services Offerings
        • 5.4.7.3. Financial Analysis
        • 5.4.7.4. SWOT Analysis
      • 5.4.8. F. Hoffmann-La Roche Ltd (Basel, Switzerland)
        • 5.4.8.1. Business Overview
        • 5.4.8.2. Products/Services Offerings
        • 5.4.8.3. Financial Analysis
        • 5.4.8.4. SWOT Analysis
      • 5.4.9. Verrian (Wilmington, United States)
        • 5.4.9.1. Business Overview
        • 5.4.9.2. Products/Services Offerings
        • 5.4.9.3. Financial Analysis
        • 5.4.9.4. SWOT Analysis
      • 5.4.10. Mind Medicine (New York, United States)
        • 5.4.10.1. Business Overview
        • 5.4.10.2. Products/Services Offerings
        • 5.4.10.3. Financial Analysis
        • 5.4.10.4. SWOT Analysis
      • 5.4.11. Hikma Pharmaceuticals PLC (London, United Kingdom)
        • 5.4.11.1. Business Overview
        • 5.4.11.2. Products/Services Offerings
        • 5.4.11.3. Financial Analysis
        • 5.4.11.4. SWOT Analysis
      • 5.4.12. Celon Pharmaceuticals (Warsaw, Poland)
        • 5.4.12.1. Business Overview
        • 5.4.12.2. Products/Services Offerings
        • 5.4.12.3. Financial Analysis
        • 5.4.12.4. SWOT Analysis
      • 5.4.13. GH Research (Dublin, Ireland)
        • 5.4.13.1. Business Overview
        • 5.4.13.2. Products/Services Offerings
        • 5.4.13.3. Financial Analysis
        • 5.4.13.4. SWOT Analysis
      • 5.4.14. NeonMind Biosciences (Vancouver, Canada)
        • 5.4.14.1. Business Overview
        • 5.4.14.2. Products/Services Offerings
        • 5.4.14.3. Financial Analysis
        • 5.4.14.4. SWOT Analysis
      • 5.4.15. Usona Institute (Madison, United States)
        • 5.4.15.1. Business Overview
        • 5.4.15.2. Products/Services Offerings
        • 5.4.15.3. Financial Analysis
        • 5.4.15.4. SWOT Analysis
  • 6. Global Psychedelic Medicine Sale, by Application, Drug Type, End-User, Delivery Method and Region (value) (2027-2032)
    • 6.1. Introduction
    • 6.2. Global Psychedelic Medicine (Value)
      • 6.2.1. Global Psychedelic Medicine by: Application (Value)
        • 6.2.1.1. Mental Health Disorders
        • 6.2.1.2. Pain Management
        • 6.2.1.3. End-of-Life Care
        • 6.2.1.4. Existential Therapy
      • 6.2.2. Global Psychedelic Medicine by: Drug Type (Value)
        • 6.2.2.1. Psilocybin
        • 6.2.2.2. Ketamine
        • 6.2.2.3. MDMA
        • 6.2.2.4. LSD
        • 6.2.2.5. Ibogaine
        • 6.2.2.6. Ayahuasca
      • 6.2.3. Global Psychedelic Medicine by: End-User (Value)
        • 6.2.3.1. Hospitals & Clinics
        • 6.2.3.2. Clinical Research Organizations
        • 6.2.3.3. Research Institutes
      • 6.2.4. Global Psychedelic Medicine Region
        • 6.2.4.1. South America
          • 6.2.4.1.1. Brazil
          • 6.2.4.1.2. Argentina
          • 6.2.4.1.3. Rest of South America
        • 6.2.4.2. Asia Pacific
          • 6.2.4.2.1. China
          • 6.2.4.2.2. Japan
          • 6.2.4.2.3. India
          • 6.2.4.2.4. South Korea
          • 6.2.4.2.5. Taiwan
          • 6.2.4.2.6. Australia
          • 6.2.4.2.7. Rest of Asia-Pacific
        • 6.2.4.3. Europe
          • 6.2.4.3.1. Germany
          • 6.2.4.3.2. France
          • 6.2.4.3.3. Italy
          • 6.2.4.3.4. United Kingdom
          • 6.2.4.3.5. Netherlands
          • 6.2.4.3.6. Rest of Europe
        • 6.2.4.4. MEA
          • 6.2.4.4.1. Middle East
          • 6.2.4.4.2. Africa
        • 6.2.4.5. North America
          • 6.2.4.5.1. United States
          • 6.2.4.5.2. Canada
          • 6.2.4.5.3. Mexico
  • 7. Appendix
    • 7.1. Acronyms
  • 8. Methodology and Data Source
    • 8.1. Methodology/Research Approach
      • 8.1.1. Research Programs/Design
      • 8.1.2. Market Size Estimation
      • 8.1.3. Market Breakdown and Data Triangulation
    • 8.2. Data Source
      • 8.2.1. Secondary Sources
      • 8.2.2. Primary Sources
    • 8.3. Disclaimer
List of Tables
  • Table 1. Psychedelic Medicine: by Application(USD Million)
  • Table 2. Psychedelic Medicine Mental Health Disorders , by Region USD Million (2019-2024)
  • Table 3. Psychedelic Medicine Pain Management , by Region USD Million (2019-2024)
  • Table 4. Psychedelic Medicine End-of-Life Care , by Region USD Million (2019-2024)
  • Table 5. Psychedelic Medicine Existential Therapy , by Region USD Million (2019-2024)
  • Table 6. Psychedelic Medicine: by Drug Type(USD Million)
  • Table 7. Psychedelic Medicine Psilocybin , by Region USD Million (2019-2024)
  • Table 8. Psychedelic Medicine Ketamine , by Region USD Million (2019-2024)
  • Table 9. Psychedelic Medicine MDMA , by Region USD Million (2019-2024)
  • Table 10. Psychedelic Medicine LSD , by Region USD Million (2019-2024)
  • Table 11. Psychedelic Medicine Ibogaine , by Region USD Million (2019-2024)
  • Table 12. Psychedelic Medicine Ayahuasca , by Region USD Million (2019-2024)
  • Table 13. Psychedelic Medicine: by End-User(USD Million)
  • Table 14. Psychedelic Medicine Hospitals & Clinics , by Region USD Million (2019-2024)
  • Table 15. Psychedelic Medicine Clinical Research Organizations , by Region USD Million (2019-2024)
  • Table 16. Psychedelic Medicine Research Institutes , by Region USD Million (2019-2024)
  • Table 17. South America Psychedelic Medicine, by Country USD Million (2019-2024)
  • Table 18. South America Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 19. South America Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 20. South America Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 21. South America Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 22. Brazil Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 23. Brazil Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 24. Brazil Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 25. Brazil Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 26. Argentina Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 27. Argentina Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 28. Argentina Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 29. Argentina Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 30. Rest of South America Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 31. Rest of South America Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 32. Rest of South America Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 33. Rest of South America Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 34. Asia Pacific Psychedelic Medicine, by Country USD Million (2019-2024)
  • Table 35. Asia Pacific Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 36. Asia Pacific Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 37. Asia Pacific Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 38. Asia Pacific Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 39. China Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 40. China Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 41. China Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 42. China Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 43. Japan Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 44. Japan Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 45. Japan Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 46. Japan Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 47. India Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 48. India Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 49. India Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 50. India Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 51. South Korea Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 52. South Korea Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 53. South Korea Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 54. South Korea Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 55. Taiwan Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 56. Taiwan Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 57. Taiwan Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 58. Taiwan Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 59. Australia Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 60. Australia Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 61. Australia Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 62. Australia Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 63. Rest of Asia-Pacific Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 64. Rest of Asia-Pacific Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 65. Rest of Asia-Pacific Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 66. Rest of Asia-Pacific Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 67. Europe Psychedelic Medicine, by Country USD Million (2019-2024)
  • Table 68. Europe Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 69. Europe Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 70. Europe Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 71. Europe Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 72. Germany Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 73. Germany Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 74. Germany Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 75. Germany Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 76. France Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 77. France Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 78. France Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 79. France Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 80. Italy Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 81. Italy Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 82. Italy Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 83. Italy Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 84. United Kingdom Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 85. United Kingdom Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 86. United Kingdom Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 87. United Kingdom Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 88. Netherlands Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 89. Netherlands Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 90. Netherlands Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 91. Netherlands Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 92. Rest of Europe Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 93. Rest of Europe Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 94. Rest of Europe Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 95. Rest of Europe Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 96. MEA Psychedelic Medicine, by Country USD Million (2019-2024)
  • Table 97. MEA Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 98. MEA Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 99. MEA Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 100. MEA Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 101. Middle East Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 102. Middle East Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 103. Middle East Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 104. Middle East Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 105. Africa Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 106. Africa Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 107. Africa Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 108. Africa Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 109. North America Psychedelic Medicine, by Country USD Million (2019-2024)
  • Table 110. North America Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 111. North America Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 112. North America Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 113. North America Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 114. United States Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 115. United States Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 116. United States Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 117. United States Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 118. Canada Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 119. Canada Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 120. Canada Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 121. Canada Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 122. Mexico Psychedelic Medicine, by Application USD Million (2019-2024)
  • Table 123. Mexico Psychedelic Medicine, by Drug Type USD Million (2019-2024)
  • Table 124. Mexico Psychedelic Medicine, by End-User USD Million (2019-2024)
  • Table 125. Mexico Psychedelic Medicine, by Delivery Method USD Million (2019-2024)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Psychedelic Medicine: by Application(USD Million)
  • Table 142. Psychedelic Medicine Mental Health Disorders , by Region USD Million (2027-2032)
  • Table 143. Psychedelic Medicine Pain Management , by Region USD Million (2027-2032)
  • Table 144. Psychedelic Medicine End-of-Life Care , by Region USD Million (2027-2032)
  • Table 145. Psychedelic Medicine Existential Therapy , by Region USD Million (2027-2032)
  • Table 146. Psychedelic Medicine: by Drug Type(USD Million)
  • Table 147. Psychedelic Medicine Psilocybin , by Region USD Million (2027-2032)
  • Table 148. Psychedelic Medicine Ketamine , by Region USD Million (2027-2032)
  • Table 149. Psychedelic Medicine MDMA , by Region USD Million (2027-2032)
  • Table 150. Psychedelic Medicine LSD , by Region USD Million (2027-2032)
  • Table 151. Psychedelic Medicine Ibogaine , by Region USD Million (2027-2032)
  • Table 152. Psychedelic Medicine Ayahuasca , by Region USD Million (2027-2032)
  • Table 153. Psychedelic Medicine: by End-User(USD Million)
  • Table 154. Psychedelic Medicine Hospitals & Clinics , by Region USD Million (2027-2032)
  • Table 155. Psychedelic Medicine Clinical Research Organizations , by Region USD Million (2027-2032)
  • Table 156. Psychedelic Medicine Research Institutes , by Region USD Million (2027-2032)
  • Table 157. South America Psychedelic Medicine, by Country USD Million (2027-2032)
  • Table 158. South America Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 159. South America Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 160. South America Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 161. South America Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 162. Brazil Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 163. Brazil Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 164. Brazil Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 165. Brazil Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 166. Argentina Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 167. Argentina Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 168. Argentina Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 169. Argentina Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 170. Rest of South America Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 171. Rest of South America Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 172. Rest of South America Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 173. Rest of South America Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 174. Asia Pacific Psychedelic Medicine, by Country USD Million (2027-2032)
  • Table 175. Asia Pacific Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 176. Asia Pacific Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 177. Asia Pacific Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 178. Asia Pacific Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 179. China Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 180. China Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 181. China Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 182. China Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 183. Japan Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 184. Japan Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 185. Japan Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 186. Japan Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 187. India Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 188. India Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 189. India Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 190. India Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 191. South Korea Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 192. South Korea Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 193. South Korea Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 194. South Korea Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 195. Taiwan Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 196. Taiwan Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 197. Taiwan Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 198. Taiwan Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 199. Australia Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 200. Australia Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 201. Australia Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 202. Australia Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 203. Rest of Asia-Pacific Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 204. Rest of Asia-Pacific Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 205. Rest of Asia-Pacific Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 206. Rest of Asia-Pacific Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 207. Europe Psychedelic Medicine, by Country USD Million (2027-2032)
  • Table 208. Europe Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 209. Europe Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 210. Europe Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 211. Europe Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 212. Germany Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 213. Germany Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 214. Germany Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 215. Germany Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 216. France Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 217. France Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 218. France Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 219. France Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 220. Italy Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 221. Italy Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 222. Italy Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 223. Italy Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 224. United Kingdom Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 225. United Kingdom Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 226. United Kingdom Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 227. United Kingdom Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 228. Netherlands Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 229. Netherlands Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 230. Netherlands Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 231. Netherlands Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 232. Rest of Europe Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 233. Rest of Europe Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 234. Rest of Europe Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 235. Rest of Europe Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 236. MEA Psychedelic Medicine, by Country USD Million (2027-2032)
  • Table 237. MEA Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 238. MEA Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 239. MEA Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 240. MEA Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 241. Middle East Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 242. Middle East Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 243. Middle East Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 244. Middle East Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 245. Africa Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 246. Africa Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 247. Africa Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 248. Africa Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 249. North America Psychedelic Medicine, by Country USD Million (2027-2032)
  • Table 250. North America Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 251. North America Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 252. North America Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 253. North America Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 254. United States Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 255. United States Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 256. United States Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 257. United States Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 258. Canada Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 259. Canada Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 260. Canada Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 261. Canada Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 262. Mexico Psychedelic Medicine, by Application USD Million (2027-2032)
  • Table 263. Mexico Psychedelic Medicine, by Drug Type USD Million (2027-2032)
  • Table 264. Mexico Psychedelic Medicine, by End-User USD Million (2027-2032)
  • Table 265. Mexico Psychedelic Medicine, by Delivery Method USD Million (2027-2032)
  • Table 266. Research Programs/Design for This Report
  • Table 267. Key Data Information from Secondary Sources
  • Table 268. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Psychedelic Medicine: by Application USD Million (2019-2024)
  • Figure 5. Global Psychedelic Medicine: by Drug Type USD Million (2019-2024)
  • Figure 6. Global Psychedelic Medicine: by End-User USD Million (2019-2024)
  • Figure 7. South America Psychedelic Medicine Share (%), by Country
  • Figure 8. Asia Pacific Psychedelic Medicine Share (%), by Country
  • Figure 9. Europe Psychedelic Medicine Share (%), by Country
  • Figure 10. MEA Psychedelic Medicine Share (%), by Country
  • Figure 11. North America Psychedelic Medicine Share (%), by Country
  • Figure 12. Global Psychedelic Medicine share by Players 2024 (%)
  • Figure 13. Global Psychedelic Medicine share by Players (Top 3) 2024(%)
  • Figure 14. Global Psychedelic Medicine share by Players (Top 5) 2024(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AstraZeneca (Cambridge, United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. AstraZeneca (Cambridge, United Kingdom) Revenue: by Geography 2024
  • Figure 18. Cybin Corp. (Toronto, Canada) Revenue, Net Income and Gross profit
  • Figure 19. Cybin Corp. (Toronto, Canada) Revenue: by Geography 2024
  • Figure 20. Jazz Pharmaceuticals Inc. (Dublin, Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Jazz Pharmaceuticals Inc. (Dublin, Ireland) Revenue: by Geography 2024
  • Figure 22. Pfizer Inc. (New York, United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc. (New York, United States) Revenue: by Geography 2024
  • Figure 24. COMPASS Pathways (London, United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. COMPASS Pathways (London, United Kingdom) Revenue: by Geography 2024
  • Figure 26. Entheon Biomedical Corp (Vancouver, Canada) Revenue, Net Income and Gross profit
  • Figure 27. Entheon Biomedical Corp (Vancouver, Canada) Revenue: by Geography 2024
  • Figure 28. PharmaTher Holdings Ltd. (Toronto, Canada) Revenue, Net Income and Gross profit
  • Figure 29. PharmaTher Holdings Ltd. (Toronto, Canada) Revenue: by Geography 2024
  • Figure 30. F. Hoffmann-La Roche Ltd (Basel, Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche Ltd (Basel, Switzerland) Revenue: by Geography 2024
  • Figure 32. Verrian (Wilmington, United States) Revenue, Net Income and Gross profit
  • Figure 33. Verrian (Wilmington, United States) Revenue: by Geography 2024
  • Figure 34. Mind Medicine (New York, United States) Revenue, Net Income and Gross profit
  • Figure 35. Mind Medicine (New York, United States) Revenue: by Geography 2024
  • Figure 36. Hikma Pharmaceuticals PLC (London, United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Hikma Pharmaceuticals PLC (London, United Kingdom) Revenue: by Geography 2024
  • Figure 38. Celon Pharmaceuticals (Warsaw, Poland) Revenue, Net Income and Gross profit
  • Figure 39. Celon Pharmaceuticals (Warsaw, Poland) Revenue: by Geography 2024
  • Figure 40. GH Research (Dublin, Ireland) Revenue, Net Income and Gross profit
  • Figure 41. GH Research (Dublin, Ireland) Revenue: by Geography 2024
  • Figure 42. NeonMind Biosciences (Vancouver, Canada) Revenue, Net Income and Gross profit
  • Figure 43. NeonMind Biosciences (Vancouver, Canada) Revenue: by Geography 2024
  • Figure 44. Usona Institute (Madison, United States) Revenue, Net Income and Gross profit
  • Figure 45. Usona Institute (Madison, United States) Revenue: by Geography 2024
  • Figure 46. Global Psychedelic Medicine: by Application USD Million (2027-2032)
  • Figure 47. Global Psychedelic Medicine: by Drug Type USD Million (2027-2032)
  • Figure 48. Global Psychedelic Medicine: by End-User USD Million (2027-2032)
  • Figure 49. South America Psychedelic Medicine Share (%), by Country
  • Figure 50. Asia Pacific Psychedelic Medicine Share (%), by Country
  • Figure 51. Europe Psychedelic Medicine Share (%), by Country
  • Figure 52. MEA Psychedelic Medicine Share (%), by Country
  • Figure 53. North America Psychedelic Medicine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (Cambridge, United Kingdom)
  • Cybin Corp. (Toronto, Canada)
  • Jazz Pharmaceuticals Inc. (Dublin, Ireland)
  • Pfizer Inc. (New York, United States)
  • COMPASS Pathways (London, United Kingdom)
  • Entheon Biomedical Corp (Vancouver, Canada)
  • PharmaTher Holdings Ltd. (Toronto, Canada)
  • F. Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Verrian (Wilmington, United States)
  • Mind Medicine (New York, United States)
  • Hikma Pharmaceuticals PLC (London, United Kingdom)
  • Celon Pharmaceuticals (Warsaw, Poland)
  • GH Research (Dublin, Ireland)
  • NeonMind Biosciences (Vancouver, Canada)
  • Usona Institute (Madison, United States)
Select User Access Type

Key Highlights of Report


Feb 2025 208 Pages 52 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Psychedelic Medicine Market Quantitative research analysis
Global Psychedelic Medicine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca (Cambridge, United Kingdom), Cybin Corp. (Toronto, Canada), Jazz Pharmaceuticals Inc. (Dublin, Ireland), Pfizer Inc. (New York, United States), COMPASS Pathways (London, United Kingdom), Entheon Biomedical Corp (Vancouver, Canada), PharmaTher Holdings Ltd. (Toronto, Canada), F. Hoffmann-La Roche Ltd (Basel, Switzerland), Verrian (Wilmington, United States), Mind Medicine (New York, United States), Hikma Pharmaceuticals PLC (London, United Kingdom), Celon Pharmaceuticals (Warsaw, Poland), GH Research (Dublin, Ireland), NeonMind Biosciences (Vancouver, Canada) and Usona Institute (Madison, United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Psychedelic Medicine Market during projected period 2024-2032.
The Psychedelic Medicine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Psychedelic Medicine Market Report?

Have a Query? Click Here

Other Related Reports

AI-Based Robotic System for Medical Triage and Precise Diagnosis Comprehensive Study by Application (Robot-assisted Surgery, Virtual Assistants, Administrative Workflow Assistants, Connected Medical ...
$ 3800
Tourette Syndrome- Comprehensive Study by Type (Antipsychotics, Non-antipsychotics), Drug Type (Fluphenazine, Haloperidol, Risperidone, Pimozide, Tetrabenazine, Botulinum (Botox) Injections, Methylph...
$ 3800
Sanitary Napkin - Comprehensive Study by Type (Disposable Menstrual Pads, Cloth Menstrual Pads, Biodegradable Menstrual Pads), Distribution Channel (Supermarkets and Hypermarkets, Pharmacies, Conveni...
$ 3800
Men’s Hair Loss Prevention and Growth Comprehensive Study by Type (Oil, Serums, Shampoo, Conditioners, Others), Category (Organic, Conventional), Distribution Channels (Store-Based, Non-Stored-Based)...
$ 3800
Retinal Detachment Treatment Industry Comprehensive Study by Treatment (Photocoagulation (Laser surgery), Cryopexy (freezing), Pneumatic retinopexy, Scleral buckling, Vitrectomy), Condition Type (Rhe...
$ 3800
Metamucil Comprehensive Study by Application (Constipation Relief, Fiber Supplementation, Weight Management, Blood Sugar Control), Type (Powder, Capsules, Wafers, Liquid), Distribution Channels (Phar...
$ 3800